JP2018506511A5 - - Google Patents

Download PDF

Info

Publication number
JP2018506511A5
JP2018506511A5 JP2017531626A JP2017531626A JP2018506511A5 JP 2018506511 A5 JP2018506511 A5 JP 2018506511A5 JP 2017531626 A JP2017531626 A JP 2017531626A JP 2017531626 A JP2017531626 A JP 2017531626A JP 2018506511 A5 JP2018506511 A5 JP 2018506511A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
hydrogen
group
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017531626A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018506511A (ja
JP6847835B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/059525 external-priority patent/WO2016092508A1/en
Publication of JP2018506511A publication Critical patent/JP2018506511A/ja
Publication of JP2018506511A5 publication Critical patent/JP2018506511A5/ja
Application granted granted Critical
Publication of JP6847835B2 publication Critical patent/JP6847835B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017531626A 2014-12-12 2015-12-10 乳がん脳転移の処置 Expired - Fee Related JP6847835B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462091200P 2014-12-12 2014-12-12
US62/091,200 2014-12-12
PCT/IB2015/059525 WO2016092508A1 (en) 2014-12-12 2015-12-10 Treatment of breast cancer brain metastases

Publications (3)

Publication Number Publication Date
JP2018506511A JP2018506511A (ja) 2018-03-08
JP2018506511A5 true JP2018506511A5 (https=) 2019-01-24
JP6847835B2 JP6847835B2 (ja) 2021-03-24

Family

ID=55024190

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017531626A Expired - Fee Related JP6847835B2 (ja) 2014-12-12 2015-12-10 乳がん脳転移の処置

Country Status (6)

Country Link
US (1) US10689459B2 (https=)
EP (1) EP3229803B1 (https=)
JP (1) JP6847835B2 (https=)
CN (1) CN108367003B (https=)
ES (1) ES2784900T3 (https=)
WO (1) WO2016092508A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110115758B (zh) * 2018-02-05 2021-05-11 中山大学 Pik3ip1蛋白在调节t细胞反应和制备抗肿瘤药物中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
WO1992019244A2 (en) 1991-05-01 1992-11-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
DK0885002T3 (da) 1996-03-04 2011-08-22 Penn State Res Found Materialer og fremgangsmåder til forøgelse af cellulær internalisering
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
CA2336139C (en) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AU2008298948B2 (en) 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
US8354528B2 (en) 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
MX2010009743A (es) 2008-03-05 2010-09-28 Novartis Ag Uso de derivados de pirimidina para el tratamiento de las enfermedades dependientes de los receptores del factor de crecimiento epidermico (egfr) o de enfermedades que hayan adquirido resistencia a los agentes que se dirigen a los miembros de la fami
NZ607337A (en) * 2010-08-20 2015-06-26 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
AU2012349735B2 (en) 2011-12-05 2016-05-19 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
HK1211476A1 (en) 2012-08-16 2016-05-27 Novartis Ag Combination of pi3k inhibitor and c-met inhibitor
WO2014177915A1 (en) * 2013-05-01 2014-11-06 Piramal Enterprises Limited Cancer combination therapy using imidazo[4,5-c]quinoline derivatives
WO2016011167A1 (en) 2014-07-16 2016-01-21 Dana-Farber Cancer Institute, Inc., Et Al Her3 inhibition in low-grade serous ovarian cancers

Similar Documents

Publication Publication Date Title
JP7507209B2 (ja) がんを治療するための、ｐｄ－１アンタゴニスト及びｖｅｇｆｒ／ｆｇｆｒ／ｒｅｔチロシンキナーゼ阻害剤の組合せ
KR102349056B1 (ko) Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법
Awada et al. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy
CN110536905B (zh) 用于治疗肺癌的抗pd-1抗体
JP6774421B2 (ja) がんの治療のための方法、組成物、及びキット
JP2016502504A5 (https=)
JP2015534579A5 (https=)
JP2015534577A5 (https=)
JP2015534580A5 (https=)
JP2018532803A (ja) 癌を処置するためのｔｌｒ８アゴニストの使用
AU2012253858B2 (en) Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-ErbB3 agents
JP2024513505A (ja) 腫瘍を治療するための組成物及び方法
JP2020506945A (ja) がんの治療のための方法、組成物及びキット
JP2019048822A (ja) Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用
AU2017206108A1 (en) Combination of a chromene compound and a second active agent
JP2019524714A5 (https=)
US20250388682A1 (en) Degradation of egfr using a bispecific binding agent
US20220195059A1 (en) Rank Pathway Inhibitors in Combination with CDK Inhibitors
EP3893888A1 (en) Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist
JP2018506511A5 (https=)
JP2024529451A (ja) がんを治療するための方法及び組成物
WO2017176565A1 (en) Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
US20250177352A1 (en) Combination treatment for cancer
WO2014143835A1 (en) Combination/adjuvant therapy for wt-1-positive disease
Torka et al. Ofatumumab plus Hypercvad/MA induction leads to high rates of minimal residual disease (MRD) negativity in patients with newly diagnosed mantle cell lymphoma, results of a phase 2 study